-
1
-
-
79959752853
-
Anti-angiogenic therapy using brivanib, a combined VEGF and FGF pathway inhibitor, in a mouse model of pancreatic neuroendocrine cancer (PNET), results in sustained vascular blockade, without evidence for evasive/acquired resistance in the form of VEGF-independent revascularization, in contrast to other VEGF inhibitors [abstract]
-
Allen E, Walters IB, Rivera IC, Hanahan D (2009) Anti-angiogenic therapy using brivanib, a combined VEGF and FGF pathway inhibitor, in a mouse model of pancreatic neuroendocrine cancer (PNET), results in sustained vascular blockade, without evidence for evasive/acquired resistance in the form of VEGF-independent revascularization, in contrast to other VEGF inhibitors [abstract]. Mol Cancer Ther 8(Suppl 12): B16
-
(2009)
Mol Cancer Ther
, vol.8
, Issue.SUPPL. 12
-
-
Allen, E.1
Walters, I.B.2
Rivera, I.C.3
Hanahan, D.4
-
2
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8): 592-603
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
3
-
-
33645670595
-
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H- indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor
-
Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D'Arienzo C, Derbin G, Fargnoli J (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49(7): 2143-2146
-
(2006)
J Med Chem
, vol.49
, Issue.7
, pp. 2143-2146
-
-
Bhide, R.S.1
Cai, Z.W.2
Zhang, Y.Z.3
Qian, L.4
Wei, D.5
Barbosa, S.6
Lombardo, L.J.7
Borzilleri, R.M.8
Zheng, X.9
Wu, L.I.10
Barrish, J.C.11
Kim, S.H.12
Leavitt, K.13
Mathur, A.14
Leith, L.15
Chao, S.16
Wautlet, B.17
Mortillo, S.18
Jeyaseelan, R.19
Kukral, D.20
Hunt, J.T.21
Kamath, A.22
Fura, A.23
Vyas, V.24
Marathe, P.25
D'Arienzo, C.26
Derbin, G.27
Fargnoli, J.28
more..
-
4
-
-
76649108900
-
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases
-
Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan Sr R, Mortillo S, Wautlet BS, Krishnan B, Kukral D, Malone H, Lewin AC, Henley BJ, Fargnoli J (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9(2): 369-378
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.2
, pp. 369-378
-
-
Bhide, R.S.1
Lombardo, L.J.2
Hunt, J.T.3
Cai, Z.W.4
Barrish, J.C.5
Galbraith, S.6
Jeyaseelan Sr., R.7
Mortillo, S.8
Wautlet, B.S.9
Krishnan, B.10
Kukral, D.11
Malone, H.12
Lewin, A.C.13
Henley, B.J.14
Fargnoli, J.15
-
5
-
-
52649143725
-
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
-
Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G (2008) Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14(16): 5069-5080
-
(2008)
Clin Cancer Res
, vol.14
, Issue.16
, pp. 5069-5080
-
-
Bianco, R.1
Rosa, R.2
Damiano, V.3
Daniele, G.4
Gelardi, T.5
Garofalo, S.6
Tarallo, V.7
De Falco, S.8
Melisi, D.9
Benelli, R.10
Albini, A.11
Ryan, A.12
Ciardiello, F.13
Tortora, G.14
-
6
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer
-
DOI 10.1056/NEJMoa033025
-
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345 (Pubitemid 38944402)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.4
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
7
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
DOI 10.1200/JCO.2006.09.6305
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson III AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12): 1539-1544 (Pubitemid 46733080)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.12
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson III, A.B.8
-
8
-
-
59949102930
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27(5): 672-680
-
(2009)
J Clin Oncol
, vol.27
, Issue.5
, pp. 672-680
-
-
Hecht, J.R.1
Mitchell, E.2
Chidiac, T.3
Scroggin, C.4
Hagenstad, C.5
Spigel, D.6
Marshall, J.7
Cohn, A.8
McCollum, D.9
Stella, P.10
Deeter, R.11
Shahin, S.12
Amado, R.G.13
-
9
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
10
-
-
58149175849
-
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
-
Huynh H, Ngo VC, Fargnoli J, Ayers M, Soreide O, Koong HN, Thng CH, Ong HS, Chow P, Pollock P, Byron S, Tran E (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14: 6146-6153
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6146-6153
-
-
Huynh, H.1
Ngo, V.C.2
Fargnoli, J.3
Ayers, M.4
Soreide, O.5
Koong, H.N.6
Thng, C.H.7
Ong, H.S.8
Chow, P.9
Pollock, P.10
Byron, S.11
Tran, E.12
-
11
-
-
36148941301
-
Cetuximab for the treatment of colorectal cancer
-
DOI 10.1056/NEJMoa071834
-
Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20): 2040-2048 (Pubitemid 350106711)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.20
, pp. 2040-2048
-
-
Jonker, D.J.1
O'Callaghan, C.J.2
Karapetis, C.S.3
Zalcberg, J.R.4
Tu, D.5
Au, H.-J.6
Berry, S.R.7
Krahn, M.8
Price, T.9
Simes, R.J.10
Tebbutt, N.C.11
Van Hazel, G.12
Wierzbicki, R.13
Langer, C.14
Moore, M.J.15
-
12
-
-
79959691339
-
A phase i study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
-
e-pub ahead of print 3 December 2010
-
Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DS, Galbraith S (2010) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol; e-pub ahead of print 3 December 2010
-
(2010)
Ann Oncol
-
-
Jonker, D.J.1
Rosen, L.S.2
Sawyer, M.B.3
De Braud, F.4
Wilding, G.5
Sweeney, C.J.6
Jayson, G.C.7
McArthur, G.A.8
Rustin, G.9
Goss, G.10
Kantor, J.11
Velasquez, L.12
Syed, S.13
Mokliatchouk, O.14
Feltquate, D.M.15
Kollia, G.16
Nuyten, D.S.17
Galbraith, S.18
-
13
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1): 60-65
-
(2003)
J Clin Oncol
, vol.21
, Issue.1
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
Meropol, N.J.4
Novotny, W.F.5
Lieberman, G.6
Griffing, S.7
Bergsland, E.8
-
14
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17): 1757-1765
-
(2008)
N Engl J Med
, vol.359
, Issue.17
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
O'Callaghan, C.J.4
Tu, D.5
Tebbutt, N.C.6
Simes, R.J.7
Chalchal, H.8
Shapiro, J.D.9
Robitaille, S.10
Price, T.J.11
Shepherd, L.12
Au, H.J.13
Langer, C.14
Moore, M.J.15
Zalcberg, J.R.16
-
15
-
-
20244376908
-
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
-
DOI 10.1158/1078-0432.CCR-04-2626
-
Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'Shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11(8): 2785-2808 (Pubitemid 40525178)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.8
, pp. 2785-2808
-
-
Kelloff, G.J.1
Hoffman, J.M.2
Johnson, B.3
Scher, H.I.4
Siegel, B.A.5
Cheng, E.Y.6
Cheson, B.D.7
O'Shaughnessy, J.8
Guyton, K.Z.9
Mankoff, D.A.10
Shankar, L.11
Larson, S.M.12
Sigman, C.C.13
Schilsky, R.L.14
Sullivan, D.C.15
-
16
-
-
43249095919
-
Tumor angiogenesis
-
DOI 10.1056/NEJMra0706596
-
Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19): 2039-2049 (Pubitemid 351656458)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.19
, pp. 2039-2049
-
-
Kerbel, R.S.1
-
17
-
-
79959692106
-
Angiogenic cytokines are increased prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab
-
Presented at 15-17 January; San Francisco, CA, USA. Abstract 292
-
Kopetz S, Hoff PM, Eng MJ, Overman KY, Glover DZ, Chang RA, Abbruzzese JL, Ellis LM, Heymach JV (2009) Angiogenic cytokines are increased prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. Presented at: ASCO Gastrointestinal Cancers Symposium, 15-17 January; San Francisco, CA, USA. Abstract 292
-
(2009)
ASCO Gastrointestinal Cancers Symposium
-
-
Kopetz, S.1
Hoff, P.M.2
Eng, M.J.3
Overman, K.Y.4
Glover, D.Z.5
Chang, R.A.6
Abbruzzese, J.L.7
Ellis, L.M.8
Heymach, J.V.9
-
18
-
-
66149163097
-
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
-
Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Janne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV (2009) Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15(10): 3484-3494
-
(2009)
Clin Cancer Res
, vol.15
, Issue.10
, pp. 3484-3494
-
-
Naumov, G.N.1
Nilsson, M.B.2
Cascone, T.3
Briggs, A.4
Straume, O.5
Akslen, L.A.6
Lifshits, E.7
Byers, L.A.8
Xu, L.9
Wu, H.K.10
Janne, P.11
Kobayashi, S.12
Halmos, B.13
Tenen, D.14
Tang, X.M.15
Engelman, J.16
Yeap, B.17
Folkman, J.18
Johnson, B.E.19
Heymach, J.V.20
more..
-
19
-
-
79953325932
-
Open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
-
Park JW, Finn RS, Kim SJ, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul J-L (2011) Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 7(7): 1973-1983
-
Clin Cancer Res
, vol.7
, Issue.7
, pp. 1973-1983
-
-
Park, J.W.1
Finn, R.S.2
Kim, S.J.3
Kim, J.S.4
Karwal, M.5
Li, R.K.6
Ismail, F.7
Thomas, M.8
Harris, R.9
Baudelet, C.10
Walters, I.11
-
20
-
-
35648941728
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
-
DOI 10.1200/JCO.2007.12.0949
-
Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25(29): 4557-4561 (Pubitemid 350035312)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.29
, pp. 4557-4561
-
-
Saltz, L.B.1
Lenz, H.-J.2
Kindler, H.L.3
Hochster, H.S.4
Wadler, S.5
Hoff, P.M.6
Kemeny, N.E.7
Hollywood, E.M.8
Gonen, M.9
Quinones, M.10
Morse, M.11
Chen, H.X.12
-
21
-
-
44249111440
-
EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
-
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris III HA (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26(14): 2311-2319
-
(2008)
J Clin Oncol
, vol.26
, Issue.14
, pp. 2311-2319
-
-
Sobrero, A.F.1
Maurel, J.2
Fehrenbacher, L.3
Scheithauer, W.4
Abubakr, Y.A.5
Lutz, M.P.6
Vega-Villegas, M.E.7
Eng, C.8
Steinhauer, E.U.9
Prausova, J.10
Lenz, H.J.11
Borg, C.12
Middleton, G.13
Kroning, H.14
Luppi, G.15
Kisker, O.16
Zubel, A.17
Langer, C.18
Kopit, J.19
Burris Iii, H.A.20
more..
-
22
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6): 563-572
-
(2009)
N Engl J Med
, vol.360
, Issue.6
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
Rodenburg, C.J.4
Creemers, G.J.5
Schrama, J.G.6
Erdkamp, F.L.7
Vos, A.H.8
Van Groeningen, C.J.9
Sinnige, H.A.10
Richel, D.J.11
Voest, E.E.12
Dijkstra, J.R.13
Vink-Borger, M.E.14
Antonini, N.F.15
Mol, L.16
Van Krieken, J.H.17
Dalesio, O.18
Punt, C.J.19
-
23
-
-
70349650689
-
Repeatability of 18F-FDG PET in a multicenter phase i study of patients with advanced gastrointestinal malignancies
-
Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, Lammertsma AA, Galbraith SM (2009) Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 50(10): 1646-1654
-
(2009)
J Nucl Med
, vol.50
, Issue.10
, pp. 1646-1654
-
-
Velasquez, L.M.1
Boellaard, R.2
Kollia, G.3
Hayes, W.4
Hoekstra, O.S.5
Lammertsma, A.A.6
Galbraith, S.M.7
-
24
-
-
0032757213
-
18F]- fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
-
DOI 10.1016/S0959-8049(99)00229-4, PII S0959804999002294
-
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13): 1773-1782 (Pubitemid 29512308)
-
(1999)
European Journal of Cancer
, vol.35
, Issue.13
, pp. 1773-1782
-
-
Young, H.1
Baum, R.2
Cremerius, U.3
Herholz, K.4
Hoekstra, O.5
Lammertsma, A.A.6
Pruim, J.7
Price, P.8
|